Contingency Management for Drug Use: Does Age Matter?
Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Aug 26, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Contingency Management for Drug Use: Does Age Matter?", is studying whether using a smartphone app that offers rewards can help older adults who struggle with substance use disorders, such as opioid, methamphetamine, or cocaine abuse. The researchers want to find out if older participants are willing to engage with this app and how effective it is for them compared to younger individuals. By understanding these factors, the study aims to improve treatment options for older adults dealing with substance use issues.
To be eligible for this trial, participants need to be at least 18 years old, diagnosed with a substance use disorder, and have access to a smartphone where they can download the DynamiCare app. Participants should also be currently receiving treatment for their substance use. Those who join the study can expect to use the app to track their progress and receive rewards for meeting certain goals. This study is currently recruiting participants and aims to provide valuable insights into how age affects the success of app-based treatment approaches.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age at least 18 years old;
- • Meet DSM-5 OUD, CoUD, or MUD criteria as evidenced by an OUD CPT code F11\* (opioid related disorders), a CoUD CPT code F14\* (cocaine related disorders), a MUD CPT code F15.1/F15.2 or other clinical notes indicating illicit opioid/cocaine/methamphetamine use for treatment;
- • Have access to a smartphone (iOS or Android) with data plan and willing to download DynamiCare app;
- • Have an email and can access it from their smartphone;
- • Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment;
- * Are likely to be helped by contingency management because at least ONE of the following conditions is true:
- • 1. Were first enrolled in residential, PHP, or IOP substance use treatment no longer than 2 treatment weeks (14 days/encounters of treatment) prior to providing informed consent.
- • 2. Used non-medical opioids, cocaine, and/or methamphetamine within the last 21 days.
- • Understands English.
- Exclusion Criteria:
- • Have evidence of active (non-substance related) psychosis that might impair participation as determined by the PI.
- • Has significant cognitive impairment that might confound participation as determined by the PI or are so significantly cognitively impaired that they have a legal guardian.
About Wake Forest University Health Sciences
Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oconomowoc, Wisconsin, United States
Chicago, Illinois, United States
Milwaukee, Wisconsin, United States
Patients applied
Trial Officials
Mercedes Robaina
Principal Investigator
Wake Forest University Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials